Matrix Metalloproteinase-2 and -9 in Glioblastoma: A Trio of Old Drugs-Captopril, Disulfiram and Nelfinavir-Are Inhibitors with Potential as Adjunctive Treatments in Glioblastoma

Archives of Medical Research

Volumn 43, Issue 3, 2012, Pages 243-247

  Kast, Richard E ^a   Halatsch, Marc Eric ^b  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

Adjunct; Captopril; Chemotherapy; Disulfiram; Glioblastoma; Matrix metalloproteinase; Nelfinavir; Stem cell

Indexed keywords

CAPTOPRIL; DISULFIRAM; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE; GELATINASE A; GELATINASE B; HERMES ANTIGEN; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; NELFINAVIR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; STAT3 PROTEIN; TEMOZOLOMIDE; TUMOR NECROSIS FACTOR ALPHA; UROKINASE; VASCULOTROPIN; VITRONECTIN RECEPTOR;

ADJUVANT THERAPY; ALCOHOLISM; ARTICLE; BLOOD BRAIN BARRIER; BRAIN TISSUE; CANCER CELL CULTURE; CANCER GROWTH; CANCER SURGERY; CELL MIGRATION; DRUG EXPOSURE; DRUG INDUCED HEADACHE; DRUG PENETRATION; ENZYME ACTIVITY; ENZYME INHIBITION; FLUSHING; GLIOBLASTOMA; HEART FAILURE; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALAISE; MUCOCUTANEOUS LYMPH NODE SYNDROME; NAUSEA; PERITONEAL DIALYSIS; PROSTATE CANCER; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RENAL PROTECTION; SIDE EFFECT; SINGLE DRUG DOSE; TUMOR RECURRENCE; TUMOR VASCULARIZATION; VOMITING;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BRAIN NEOPLASMS; CAPTOPRIL; CHEMOTHERAPY, ADJUVANT; DISULFIRAM; GLIOBLASTOMA; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASE INHIBITORS; NELFINAVIR;

EID: 84862229701     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2012.04.005     Document Type: Article

References (53)

1. Hargrave D. Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy. Br J Neurosurg 2009, 23:351-363.
2. Löw S., Vougioukas V.I., Hielscher T., et al. Pathogenetic pathways leading to glioblastoma multiforme: association between gene expressions and resistance to erlotinib. Anticancer Res 2008, 28:3729-3732.
3. Halatsch M.E. Targeted therapy for glioblastoma multiforme. Anticancer Agents Med Chem 2011, 17. (Epub ahead of print) PubMed PMID: 21864239.
4. Preusser M., de Ribaupierre S., Wöhrer A., et al. Current concepts and management of glioblastoma. Ann Neurol 2011, 70:9-21.
5. Stern J.C.S. Civil Military Operations & Military Information Support Operations Coordination: A Non-Kinetic Ballast for Disciplined Counterinsurgency Operations. smallwarsjournal.com 2011.
6. Nakada M., Okada Y., Yamashita J. The role of matrix metalloproteinases in glioma invasion. Front Biosci 2003, 8:e261-e269.
7. Rao J.S., Steck P.A., Mohanam S., et al. Elevated levels of M(r) 92,000 type IV collagenase in human brain tumors. Cancer Res 1993, 53(10 suppl):2208-22011.
8. Das G., Shiras A., Shanmuganandam K., et al. Rictor regulates MMP-9 activity and invasion through Raf-1-MEK-ERK signaling pathway in glioma cells. Mol Carcinog 2011, 50:412-423.
9. Rao J.S., Yamamoto M., Mohaman S., et al. Expression and localization of 92 kDa type IV collagenase/gelatinase B (MMP-9) in human gliomas. Clin Exp Metastasis 1996, 14:12-18.
10. Tews D.S., Nissen A. Expression of adhesion factors and degrading proteins in primary and secondary glioblastomas and their precursor tumors. Invasion Metastasis 1998-1999, 18:271-284.
11. Comincini S., Paolillo M., Barbieri G., et al. Gene expression analysis of an EGFR indirectly related pathway identified PTEN and MMP9 as reliable diagnostic markers for human glial tumor specimens. J Biomed Biotechnol 2009, 2009:924565.
12. Jiang R., Mircean C., Shmulevich I., et al. Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays. Proteomics 2006, 6:2964-2971.
13. Komatsu K., Nakanishi Y., Nemoto N., et al. Expression and quantitative analysis of matrix metalloproteinase-2 and -9 in human gliomas. Brain Tumor Pathol 2004, 21:105-112.
14. Kunishio K., Okada M., Matsumoto Y., et al. Matrix metalloproteinase-2 and -9 expression in astrocytic tumors. Brain Tumor Pathol 2003, 20:39-45.
15. Choe G., Park J.K., Jouben-Steele L., et al. Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype. Clin Cancer Res 2002, 8:2894-2901.
16. Vince G.H., Wagner S., Pietsch T., et al. Heterogeneous regional expression patterns of matrix metalloproteinases in human malignant gliomas. Int J Dev Neurosci 1999, 17:437-445.
17. Munaut C., Noël A., Hougrand O., et al. Vascular endothelial growth factor expression correlates with matrix metalloproteinases MT1-MMP, MMP-2 and MMP-9 in human glioblastomas. Int J Cancer 2003, 106:848-855.
18. Raithatha S.A., Muzik H., Muzik H., et al. Localization of gelatinase-A and gelatinase-B mRNA and protein in human gliomas. Neuro Oncol 2000, 2:145-150.
19. Zhao Y., Lyons C.E., Xiao A., et al. Urokinase directly activates matrix metalloproteinases-9: a potential role in glioblastoma invasion. Biochem Biophys Res Commun 2008, 369:1215-1220.
20. van Hinsbergh V.W., Engelse M.A., Quax P.H. Pericellular proteases in angiogenesis and vasculogenesis. Arterioscler Thromb Vasc Biol 2006, 26:716-728.
21. Hagemann C., Anacker J., Haas S., et al. Comparative expression pattern of matrix-metalloproteinases in human glioblastoma cell-lines and primary cultures. BMC Res Notes 2010, 3:293.
22. Hormigo A., Gu B., Karimi S., et al. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res 2006, 12:5698-5704.
23. Pagenstecher A., Wussler E.M., Opdenakker G., et al. Distinct expression patterns and levels of enzymatic activity of matrix metalloproteinases and their inhibitors in primary brain tumors. J Neuropathol Exp Neurol 2001, 60:598-612.
24. Zhang W., Lin Y., Chen B., et al. Recurrent glioblastoma of childhood treated with bevacizumab: case report and molecular features. Childs Nerv Syst 2010, 26:137-143.
25. Nakagawa T., Kubota T., Kabuto M., et al. Production of matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 by human brain tumors. J Neurosurg 1994, 81:69-77.
26. Forsyth P.A., Laing T.D., Gibson A.W., et al. High levels of gelatinase-B and active gelatinase-A in metastatic glioblastoma. J Neurooncol 1998, 36:21-29.
27. Iwamoto F.M., Hottinger A.F., Karimi S., et al. Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas. J Neurooncol 2011, 105:607-612.
28. Yan W., Zhang W., Sun L., et al. Identification of MMP-9 specific microRNA expression profile as potential targets of anti-invasion therapy in glioblastoma multiforme. Brain Res 2011, 1411:108-115.
29. Marcus H.J., Carpenter K.L., Price S.J., et al. In vivo assessment of high-grade glioma biochemistry using microdialysis: a study of energy-related molecules, growth factors and cytokines. J Neurooncol 2010, 97:11-23.
30. Young J.B. Angiotensin-converting enzyme inhibitors in heart failure: new strategies justified by recent clinical trials. Int J Cardiol 1994, 43:151-163.
31. Heel R.C., Brogden R.N., Speight T.M., et al. Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy. Drugs 1980, 20:409-452.
32. Sorbi D., Fadly M., Hicks R., et al. Captopril inhibits the 72 kDa and 92 kDa matrix metalloproteinases. Kidney Int 1993, 44:1266-1272.
33. Rooprai H.K., Kandanearatchi A., Maidment S., et al. Evaluation of the effects of swainsonine, captopril, tangeretin and nobiletin on the biological behaviour of brain tumour cells in vitro. Neuropathol Appl Neurobiol 2001, 27:29-39.
34. Nakagawa T., Kubota T., Kabuto M., et al. Captopril inhibits glioma cell invasion in vitro: involvement of matrix metalloproteinases. Anticancer Res 1995, 15:1985-1989.
35. Geppetti P., Spillantini M.G., Frilli S., et al. Acute oral captopril inhibits angiotensin converting enzyme activity in human cerebrospinal fluid. J Hypertens 1987, 5:151-154.
36. Inoue N., Takai S., Jin D., et al. Effect of angiotensin-converting enzyme inhibitor on matrix metalloproteinase-9 activity in patients with Kawasaki disease. Clin Chim Acta 2010, 411:267-269.
37. Reinhardt D., Sigusch H.H., Hensse J., et al. Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP. Heart 2002, 88:525-530.
38. Efsen E., Saermark T., Hansen A., et al. Ramiprilate inhibits functional matrix metalloproteinase activity in Crohn's disease fistulas. Basic Clin Pharmacol Toxicol 2011, 109:208-216.
39. Nordström M., Abrahamsson T., Ervik M., et al. Central nervous and systemic kinetics of ramipril and ramiprilat in the conscious dog. J Pharmacol Exp Ther 1993, 266:147-152.
40. De Barros S., Zakaroff-Girard A., Lafontan M., et al. Inhibition of human preadipocyte proteasomal activity by HIV protease inhibitors or specific inhibitor lactacystin leads to a defect in adipogenesis, which involves matrix metalloproteinase-9. J Pharmacol Exp Ther 2007, 320:291-299.
41. Yang Y., Ikezoe T., Takeuchi T., et al. HIV-1 protease inhibitor induces growth arrest and apoptosis of human prostate cancer LNCaP cells in vitro and in vivo in conjunction with blockade of androgen receptor STAT3 and AKT signaling. Cancer Sci 2005, 96:425-433.
42. Rahaman S.O., Harbor P.C., Chernova O., et al. Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene 2002, 21:8404-8413.
43. Loeffler S., Fayard B., Weis J., et al. Interleukin-6 induces transcriptional activation of vascular endothelial growth factor (VEGF) in astrocytes in vivo and regulates VEGF promoter activity in glioblastoma cells via direct interaction between STAT3 and Sp1. Int J Cancer 2005, 115:202-213.
44. Brantley E.C., Benveniste E.N. Signal transducer and activator of transcription-3: a molecular hub for signaling pathways in gliomas. Mol Cancer Res 2008, 6:675-684.
45. Li R., Li G., Deng L., et al. IL-6 augments the invasiveness of U87MG human glioblastoma multiforme cells via up-regulation of MMP-2 and fascin-1. Oncol Rep 2010, 23:1553-1559.
46. Liu Q., Li G., Li R., et al. IL-6 promotion of glioblastoma cell invasion and angiogenesis in U251 and T98G cell lines. J Neurooncol 2010, 100:165-176.
47. Bourlier V., Zakaroff-Girard A., De Barros S., et al. Protease inhibitor treatments reveal specific involvement of matrix metalloproteinase-9 in human adipocyte differentiation. J Pharmacol Exp Ther 2005, 312:1272-1279.
48. Shian S.G., Kao Y.R., Wu F.Y., et al. Inhibition of invasion and angiogenesis by zinc-chelating agent disulfiram. Mol Pharmacol 2003, 64:1076-1084.
49. Cho H.J., Lee T.S., Park J.B., et al. Disulfiram suppresses invasive ability of osteosarcoma cells via the inhibition of MMP-2 and MMP-9 expression. J Biochem Mol Biol 2007, 40:1069-1076.
50. Moreb J.S., Ucar D., Han S., et al. The enzymatic activity of human aldehyde dehydrogenases 1A2 and 2 (ALDH1A2 and ALDH2) is detected by Aldefluor, inhibited by diethylaminobenzaldehyde and has significant effects on cell proliferation and drug resistance. Chem Biol Interact 2012, 195:52-60.
51. Yip N.C., Fombon I.S., Liu P., et al. Disulfiram modulated ROS-MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties. Br J Cancer 2011, 104:1564-1574.
52. Kast R.E., Belda-Iniesta C. Suppressing glioblastoma stem cell function by aldehyde dehydrogenase inhibition with chloramphenicol or disulfiram as a new treatment adjunct: an hypothesis. Curr Stem Cell Res Ther 2009, 4:314-317.
53. Siegelin M.D., Plescia J., Raskett C.M., et al. Global targeting of subcellular heat shock protein-90 networks for therapy of glioblastoma. Mol Cancer Ther 2010, 9:1638-1646.